Pharmacy Grand Rounds
It’s The Circle of Neratinib: The Role of Neratinib in Metastatic HER2-Positive Breast Cancer

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

The introduction of the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor neratinib presents a unique approach to the treatment of HER2-positive breast cancer. Neratinib has demonstrated efficacy in advanced, metastatic disease in combination with capecitabine and early stage disease as a single agent in extended adjuvant treatment. This presentation will review the role of neratinib in the treatment of HER2-positive metastatic breast cancer and discuss management strategies to reduce adverse events associated with neratinib.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Review the current treatment strategies for metastatic HER2-positive breast cancer.
• Discuss the role of neratinib in the treatment of metastatic HER2-positive breast cancer.
• Identify management strategies to reduce adverse events associated with neratinib

Session Announcement

Session Slides

FACULTY INFORMATION

Katharine Damico, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Health System - Lacrosse, WI

Katharine received a Doctor of Pharmacy degree from Duquesne University in Pittsburgh, PA.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Health System – La Crosse with clinical practice interests in oncology and critical care.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Katharine Damico, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS